FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945280131> ?p ?o ?g. }

• W2945280131 endingPage "362" @default.
• W2945280131 startingPage "353" @default.
• W2945280131 abstract "Abstract The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic therapy. Patients were randomized to rituximab (375 mg/m2 IV on day 1 of weeks 1-4 and repeated during weeks 12-15 in responding patients) or rituximab (same schedule) in combination with lenalidomide (15 mg orally daily for 18 weeks). Primary end point was complete response (CR)/unconfirmed CR (CRu) rate at 6 months. In total, 77 patients were allocated to rituximab monotherapy and 77 to the combination (47% poor-risk Follicular Lymphoma International Prognostic Index score in each arm). A significantly higher CR/CRu rate at 6 months was documented in the combination arm by the investigators (36%; 95% confidence interval [CI], 26%-48% vs 25%; 95% CI, 16%-36%) and confirmed by an independent response review of computed tomography scans only (61%; 95% CI, 49%-72% vs 36%; 95% CI, 26%-48%). After a median follow-up of 4 years, significantly higher 30-month CR/CRu rates and longer progression-free survival (PFS) and time to next treatment (TTNT) were observed for the combination. Overall survival (OS) rates were similar in both arms (≥90%). Toxicity grade ≥3 was more common in the combination arm (56% vs 22% of patients), mainly represented by neutropenia (23% vs 7%). Addition of lenalidomide to rituximab significantly improved CR/CRu rates, PFS, and TTNT, with expected higher, but manageable toxicity. The excellent OS in both arms suggests that chemotherapy-free strategies should be further explored. This trial was registered at www.clinicaltrials.gov as #NCT01307605." @default.
• W2945280131 created "2019-05-29" @default.
• W2945280131 creator A5007978440 @default.
• W2945280131 creator A5008022418 @default.
• W2945280131 creator A5016787940 @default.
• W2945280131 creator A5020563845 @default.
• W2945280131 creator A5020899451 @default.
• W2945280131 creator A5024432639 @default.
• W2945280131 creator A5028859410 @default.
• W2945280131 creator A5036985315 @default.
• W2945280131 creator A5037713780 @default.
• W2945280131 creator A5040624896 @default.
• W2945280131 creator A5041567047 @default.
• W2945280131 creator A5041795237 @default.
• W2945280131 creator A5045139107 @default.
• W2945280131 creator A5045311601 @default.
• W2945280131 creator A5046258011 @default.
• W2945280131 creator A5050974067 @default.
• W2945280131 creator A5058698120 @default.
• W2945280131 creator A5065902991 @default.
• W2945280131 creator A5071945736 @default.
• W2945280131 creator A5072124785 @default.
• W2945280131 creator A5073165908 @default.
• W2945280131 creator A5074920774 @default.
• W2945280131 creator A5082943014 @default.
• W2945280131 creator A5089760889 @default.
• W2945280131 creator A5090350899 @default.
• W2945280131 creator A5091441095 @default.
• W2945280131 date "2019-07-25" @default.
• W2945280131 modified "2023-10-18" @default.
• W2945280131 title "Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy" @default.
• W2945280131 cites W1912693401 @default.
• W2945280131 cites W1971050658 @default.
• W2945280131 cites W1982790762 @default.
• W2945280131 cites W2025658051 @default.
• W2945280131 cites W2030638302 @default.
• W2945280131 cites W2031025766 @default.
• W2945280131 cites W2058763863 @default.
• W2945280131 cites W2099308699 @default.
• W2945280131 cites W2101648653 @default.
• W2945280131 cites W2107767587 @default.
• W2945280131 cites W2108131857 @default.
• W2945280131 cites W2114233385 @default.
• W2945280131 cites W2116895103 @default.
• W2945280131 cites W2132103750 @default.
• W2945280131 cites W2133201432 @default.
• W2945280131 cites W2135321054 @default.
• W2945280131 cites W2138404218 @default.
• W2945280131 cites W2138594464 @default.
• W2945280131 cites W2139176812 @default.
• W2945280131 cites W2145785161 @default.
• W2945280131 cites W2149721689 @default.
• W2945280131 cites W2155724413 @default.
• W2945280131 cites W2156522119 @default.
• W2945280131 cites W2157749844 @default.
• W2945280131 cites W2169014774 @default.
• W2945280131 cites W2169209759 @default.
• W2945280131 cites W2178345923 @default.
• W2945280131 cites W2198559016 @default.
• W2945280131 cites W2301801626 @default.
• W2945280131 cites W2566546873 @default.
• W2945280131 cites W2753889266 @default.
• W2945280131 cites W2761878534 @default.
• W2945280131 cites W2768771216 @default.
• W2945280131 cites W2891543930 @default.
• W2945280131 cites W2925270992 @default.
• W2945280131 cites W4206396850 @default.
• W2945280131 cites W4249178543 @default.
• W2945280131 doi "https://doi.org/10.1182/blood-2018-10-879643" @default.
• W2945280131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31101627" @default.
• W2945280131 hasPublicationYear "2019" @default.
• W2945280131 type Work @default.
• W2945280131 sameAs 2945280131 @default.
• W2945280131 citedByCount "44" @default.
• W2945280131 countsByYear W29452801312019 @default.
• W2945280131 countsByYear W29452801312020 @default.
• W2945280131 countsByYear W29452801312021 @default.
• W2945280131 countsByYear W29452801312022 @default.
• W2945280131 countsByYear W29452801312023 @default.
• W2945280131 crossrefType "journal-article" @default.
• W2945280131 hasAuthorship W2945280131A5007978440 @default.
• W2945280131 hasAuthorship W2945280131A5008022418 @default.
• W2945280131 hasAuthorship W2945280131A5016787940 @default.
• W2945280131 hasAuthorship W2945280131A5020563845 @default.
• W2945280131 hasAuthorship W2945280131A5020899451 @default.
• W2945280131 hasAuthorship W2945280131A5024432639 @default.
• W2945280131 hasAuthorship W2945280131A5028859410 @default.
• W2945280131 hasAuthorship W2945280131A5036985315 @default.
• W2945280131 hasAuthorship W2945280131A5037713780 @default.
• W2945280131 hasAuthorship W2945280131A5040624896 @default.
• W2945280131 hasAuthorship W2945280131A5041567047 @default.
• W2945280131 hasAuthorship W2945280131A5041795237 @default.
• W2945280131 hasAuthorship W2945280131A5045139107 @default.
• W2945280131 hasAuthorship W2945280131A5045311601 @default.
• W2945280131 hasAuthorship W2945280131A5046258011 @default.
• W2945280131 hasAuthorship W2945280131A5050974067 @default.
• W2945280131 hasAuthorship W2945280131A5058698120 @default.
• W2945280131 hasAuthorship W2945280131A5065902991 @default.

• next